Evaluation of WO2013117503 and WO2013117504: the use of PI3K inhibitors to treat cough or idiopathic pulmonary fibrosis.

Abstract

Two applications claim the use of the closely related, broad spectrum phosphatidylinositol 3-kinase inhibitors 2,4-difluoro-N-{2-(methoxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide (GSK-2126458) and 2,4-difluoro-N-{2-(methoxy)-5-[4-(4-morpholino)-6-quinazolinyl]-3-pyridinyl}benzenesulfonamide for the treatment of idiopathic pulmonary fibrosis and cough, respectively. Some in vitro data are presented in support of these claimed utilities. Since the filing of these applications, GSK-2126458 has commenced a dose-finding Phase I study in patients with idiopathic pulmonary fibrosis.

• Authors: Peter Norman
• Journal: Expert opinion on therapeutic patents (Expert Opin Ther Pat) Vol. 24 Issue 6 Pg. 719-22 (Jun 2014) ISSN: 1744-7674 [Electronic] England
• PMID: 24392766 (Publication Type: Journal Article)

Chemical References

• Phosphoinositide-3 Kinase Inhibitors
• Protein Kinase Inhibitors
• Pyridazines
• Quinolines
• Sulfonamides
• omipalisib
• Proto-Oncogene Proteins c-akt

Topics

• Cough (drug therapy)
• Drug Discovery
• Fibroblasts (drug effects, physiology)
• Humans
• Patents as Topic
• Phosphoinositide-3 Kinase Inhibitors
• Phosphorylation
• Protein Kinase Inhibitors (therapeutic use)
• Proto-Oncogene Proteins c-akt (metabolism)
• Pulmonary Fibrosis (drug therapy)
• Pyridazines
• Quinolines (chemical synthesis, therapeutic use)
• Sulfonamides (chemical synthesis, therapeutic use)